港股異動 | 百濟神州(6160.HK)大漲12%創歷史新高 市值超3100億港元!
格隆匯9月17日丨百濟神州(6160.HK)高開高走,現大漲11.92%報259.2港元,股價創歷史新高,暫成交1.25億港元,市值3135億港元;該股迄今已連續6個交易日上漲,累漲約27%。百濟神州近日公佈,獲FDA(美國食品藥品監督管理局)授予百悦澤(澤布替尼)加速批准,用於治療接受過至少一次抗CD20治療的復發或難治性(R/R)邊緣區淋巴瘤(MZL)成年患者。加速批准基於總緩解率(ORR)結果。目前,除美國和中國以外,共有30多項百悦澤針對多項適應症的相關上市申請完成遞交工作,覆蓋歐盟以及其他20多個國家。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.